Not available
Quote | vTv Therapeutics Inc. (NASDAQ:VTVT)
Last: | $23.53 |
---|---|
Change Percent: | 0.0% |
Open: | $24.36 |
Close: | $23.53 |
High: | $25.07 |
Low: | $22.81 |
Volume: | 15,155 |
Last Trade Date Time: | 03/28/2024 03:00:00 am |
News | vTv Therapeutics Inc. (NASDAQ:VTVT)
2024-03-26 07:37:54 ET More on Viking Therapeutics Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront Viking Therapeutics: Here To Stay In Obesity, Or A Flash In The Pan? Viking Therapeutics: VK2735 Data Supports A Buyout Jefferies start...
CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT PR Newswire Podium presentation will include clinical updates from the Company's Phase 2 clinical trials investigating azeliragon, in combination with radiation therapy with or without temozol...
Message Board Posts | vTv Therapeutics Inc. (NASDAQ:VTVT)
Subject | By | Source | When |
---|---|---|---|
2 week long runs in past on news | 81vette | investorshub | 03/06/2023 5:28:28 PM |
Zero borrow and not optionable,low float target $4,insider | 81vette | investorshub | 03/06/2023 3:06:16 PM |
Zero borrow and not optionable,low float target $4,insider | 81vette | investorshub | 03/06/2023 3:06:15 PM |
https://finviz.com/quote.ashx?t=VTVT&ty=c&ta=1&p=d | TheFinalCD | investorshub | 02/27/2023 1:03:17 PM |
whytestocks: $VTVT News Article - vTv Therapeutics Announces Paul Sekhri as new President and Chief | whytestocks | investorshangout | 07/27/2022 12:11:01 PM |
News, Short Squeeze, Breakout and More Instantly...
vTv Therapeutics Inc. Company Name:
VTVT Stock Symbol:
NASDAQ Market:
vTv Therapeutics Inc. Website:
CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT PR Newswire Podium presentation will include clinical updates from the Company's Phase 2 clinical trials investigating azeliragon, in combination with radiation therapy with or without temozol...
2024-03-17 21:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Recently completed $51 million PIPE from healthcare-focused institutional investors and the JDRF T1D Fund. Company's first Phase 3 clinical trial of cadisegliatin (TTP399), an oral adjunctive therapy to insulin, for the treatment of type 1 diabetes, expected to initiate patient enroll...